ProQR Therapeutics (PRQR) Cash from Financing Activities (2013 - 2026)

ProQR Therapeutics has reported Cash from Financing Activities for 14 years, with the latest figure at -$355906.7 in Q1 2026.

• Quarterly Cash from Financing Activities rose 32.33% year-over-year to -$355906.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 102.54% YoY) and the FY2025 annual result came in at -$2.1 million, down 102.85% from the prior year.
• Cash from Financing Activities improved to -$355906.7 in Q1 2026 per PRQR's latest filing, from -$697262.1 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $76.3 million in Q4 2024 and troughed at -$44.1 million in Q3 2022.
• A 5-year average of $2.3 million and a median of -$455185.6 in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 258.77% in 2022, then soared 6596.56% in 2024.
• Over 5 years, Cash from Financing Activities stood at $14.0 million in 2022, then slumped by 108.37% to -$1.2 million in 2023, then jumped by 6596.56% to $76.3 million in 2024, then slumped by 100.91% to -$697262.1 in 2025, then soared by 48.96% to -$355906.7 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$355906.7, -$697262.1, and -$519060.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.